Wip1 gene silencing enhances the chemosensitivity of human colon cancer cells

Xia,Zhong‑Sheng; Wu,Di; Zhong,Wa; Lu,Xi‑Ji; Yu,Tao; Chen,Qi‑Kui

doi:10.3892/ol.2017.6361

Wip1 gene silencing enhances the chemosensitivity of human colon cancer cells

Authors:
- Zhong‑Sheng Xia
- Di Wu
- Wa Zhong
- Xi‑Ji Lu
- Tao Yu
- Qi‑Kui Chen
View Affiliations

Affiliations: Department of Gastroenterology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat‑sen Memorial Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510120, P.R. China
Published online on: June 9, 2017 https://doi.org/10.3892/ol.2017.6361
Pages: 1875-1883

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colon cancer is one of the most common cancers in the world. Multidrug resistance is one of the main reasons for failure of therapy in patients with advanced colon cancer. In previous studies, multiple methods were investigated to reverse the multidrug resistance of colon cancer cells. However, to date, no clinical method has been identified to be satisfactory. Therefore, successful reversal of drug resistance in colon cancer cells still requires new therapeutic strategies or pharmaceuticals. Wild‑type p53‑induced phosphatase (Wip1), a member of the 2C type serine/threonine protein phosphatase family, is closely associated with the p53 gene, which is the most important tumor‑suppressor gene. Wip1 was reported to be associated with the chemosensitivity of breast cancer cells. However, the correlation between the expression of Wip1 gene and the chemosensitivity of colon cancer cells has not been reported yet. In the present study, Wip1‑811 small interfering RNA (siRNA) targeting Wip1 was investigated to reverse the multidrug resistance of colon cancer cells. The siRNA duplexes were transfected into RKO colon cancer cells. The messenger RNA (mRNA) expression of Wip1 was measured by reverse transcription‑quantitative polymerase chain reaction. The protein level of Wip1 was detected by western blotting. The cell viability was measured by MTS assay. The cell apoptosis and cell cycle were analyzed by flow cytometry. Intracellular adriamycin cumulative concentration was determined using flow cytometry. Wip1‑811 siRNA efficiently inhibited the expression of Wip1 at the mRNA and protein levels, and enhanced the sensitivity of RKO colon cancer cells towards chemotherapy, which was accompanied by increased cell apoptosis, following the inhibition of Wip1 gene expression. These results indicate that Wip1 gene silencing could enhance the chemosensitivity of colon cancer cells, which may provide a new potential approach for the reversal of multidrug resistance in colon cancer cells.

View Figures

View References

1	Wiseman M: The second world cancer research Fund/American institute for cancer research expert report: Food, nutrition, physical activity, and the prevention of cancer: A global perspective. Proc Nutr Soc. 67:pp. 253–256. 2008; View Article : Google Scholar : PubMed/NCBI
2	Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multiple multicentre randomised trial. Lancet. 355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
3	Redmond SM, Joncourt F, Buser K, Ziemiecki A, Altermatt HJ, Fey M, Margison G and Cerny T: Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res. 51:2092–2097. 1991.PubMed/NCBI
4	Van de Vrie W, Gheuens EE, Durante NM, De Bruijn EA, Marquet RL, Van Oosterom AT and Eggermont AM: In vitro and in vivo chemosensitizing effect of cyclosporine A on an intrinsic multidrug-resistant rat colon tumour. J Cancer Res Clin Oncol. 119:609–614. 1993. View Article : Google Scholar : PubMed/NCBI
5	Xia Z, Zhu Z, Zhang L, Royal C, Liu Z, Chen Q and Adam BL: Specific reversal of MDR1/P-gp-dependent multidrug resistance by RNA interference in colon cancer cells. Oncol Rep. 20:1433–1439. 2008.PubMed/NCBI
6	Damiani D, Michieli M, Michelutti A, Melli C, Cerno M and Baccarani M: D-verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin. Anticancer Drugs. 4:173–180. 1993. View Article : Google Scholar : PubMed/NCBI
7	Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, Woude GF Vande, O'Connor PM and Appella E: Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA. 94:pp. 6048–6053. 1997; View Article : Google Scholar : PubMed/NCBI
8	Shi Y: Serine/threonine phosphatases: Mechanism through structure. Cell. 139:468–484. 2009. View Article : Google Scholar : PubMed/NCBI
9	Donehower LA: Phosphatases reverse p53-mediated cell cycle checkpoints. Proc Natl Acad Sci USA. 111:pp. 7172–7173. 2014; View Article : Google Scholar : PubMed/NCBI
10	Lu X, Nannenga B and Donehower LA: PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 19:1162–1174. 2005. View Article : Google Scholar : PubMed/NCBI
11	Demidov ON, Timofeev O, Lwin HN, Kek C, Appella E and Bulavin DV: Wip1 phosphatase regulates p53-dependent apoptosis of stem cell and tumorigenesis in the mouse intestine. Cell Stem Cell. 1:180–190. 2007. View Article : Google Scholar : PubMed/NCBI
12	Li ZT, Zhang L, Gao XZ, Jiang XH and Sun LQ: Expression and significance of the Wip1 proto-oncogene in colorectal cancer. Asian Pac J Cancer Prev. 14:1975–1979. 2013. View Article : Google Scholar : PubMed/NCBI
13	Zhao M, Zhang H, Zhu G, Liang J, Chen N, Yang Y, Liang X, Cai H and Liu W: Association between overexpression of Wip1 and prognosis of patients with non-small cell lung cancer. Oncol Lett. 11:2365–2370. 2016.PubMed/NCBI
14	Discher DE, Janmey P and Wang YL: Tissue cells feel and repond to the stiffness of their substrate. Science. 310:1139–1143. 2005. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Li J, Xu LZ, He KL, Guo WJ, Zheng YH, Xia P and Chen Y: Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line. Breast Cancer Res. 3:253–263. 2001. View Article : Google Scholar : PubMed/NCBI
17	Chang F, Syrjänen S, Kurvinen K and Syrjänen K: The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Am J Gastroenterol. 88:174–186. 1993.PubMed/NCBI
18	Lu G and Wang Y: Functional diversity of mammalian type 2C protein phosphatase isoforms: New tales from an old family. Clin Exp Pharmacol Physiol. 35:107–112. 2008. View Article : Google Scholar : PubMed/NCBI
19	Yu E, Ahn YS, Jang SJ, Kim MJ, Yoon HS, Gong G and Choi J: Overexpression of the Wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers. Breast Cancer Res Treat. 101:269–278. 2007. View Article : Google Scholar : PubMed/NCBI
20	Baxter EW and Milner J: p53 regulates LIF expression in human medulloblastoma cells. J Neurooncol. 97:373–382. 2010. View Article : Google Scholar : PubMed/NCBI
21	Hu W, Feng Z, Modica I, Klimstra DS, Song L, Allen PJ, Brennan MF, Levine AJ and Tang LH: Gene Amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the P53 pathway. Genes Cancer. 1:360–368. 2010. View Article : Google Scholar : PubMed/NCBI
22	Zhu YH and Bulavin DV: Wip1-dependent signaling pathways in health and diseases. Prog Mol Biol Transl Sci. 106:307–325. 2012. View Article : Google Scholar : PubMed/NCBI
23	Fuku T, Semba S, Yutori H and Yokozaki H: Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma. Pathol Int. 57:566–571. 2007. View Article : Google Scholar : PubMed/NCBI
24	Nöpel-Dünnebacke S, Schulmann K, Reinacher-Schick A, Porschen R, Schmiegel W, Tannapfel A and Graeven U: Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy. Z Gastroenterol. 52:1394–1401. 2014. View Article : Google Scholar : PubMed/NCBI
25	Bisteau X, Caldez MJ and Kaldis P: The complex relationship between liver cancer and the cell cycle: A story of multiple regulations. Cancers (Basel). 6:79–111. 2014. View Article : Google Scholar : PubMed/NCBI
26	Brazina J, Svadlenka J, Macurek L, Andera L, Hodny Z, Bartek J and Hanzlikova H: DNA damage-induced regulatoryinterplay between DAXX, p53, ATM kinase and Wip1 phosphatase. Cell Cycle. 14:375–387. 2015. View Article : Google Scholar : PubMed/NCBI
27	Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, Chen H and Lu X: Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res. 70:7176–7186. 2010. View Article : Google Scholar : PubMed/NCBI